tbuckley/cabot-search huggingface dataset:
PP73. IS ROUTINE INTERVAL SURVEILLANCE IMAGING AFTER COMPLETION OF PRIMARY TREATMENT EFFECTIVE AT DETECTING RECURRENCE IN GBM PATIENTS?
Authors: Dr Alhafidz Hamdan, Prof Philip Kane
Journal: Neuro-Oncology (2017)

INTRODUCTION: There is currently no evidence on the effectiveness of routine interval scanning compared to symptomatic scanning, of glioblastoma multiforme (GBM) patients, in detecting disease progression after completion of primary treatment. This issue has now been highlighted by the Neuro-Oncology Clinical Trials UK Research Network as a priority for clinical research. METHODS: We looked at all GBM patients treated at our unit from 2004 to 2012 (N=340), and analysed those who were scanned as part of the routine interval surveillance after completion of primary treatment (Stupp protocol) or those who were scanned due to symptoms, and correlated these with diagnosis of disease progression. RESULTS: Of the 340 GBM patients, 86 (25.3%) patients were commenced on adjuvant temozolomide (after surgery/biopsy and concurrent chemoradiotherapy) and only 38 (44.2%) patients completed all 6 cycles of adjuvant temozolomide. These patients then had further scans as part of the routine interval surveillance (145 scans), or if they became symptomatic (12 scans). More symptomatic scans compared to routine interval scans detected disease progression (58.3% vs 22.7%; P= 0.018). Median time to death after a progression scan was 5.7 ± 2.6 months. No patient had disease progression after a 5th stable routine interval surveillance scan. CONCLUSION: Routine interval surveillance imaging after completion of primary treatment may identify disease progression but whether this leads to better survival remains unproven. Frequent scans are costly, and "scanxiety" may affect quality of life; whether interval scanning is justified is up for debate, given that symptomatic scanning is more predictive of disease progression. The optimum frequency of interval scanning has also not been studied. More research using a larger dataset that could enable mathematical modelling is needed to clarify this important issue.
Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations
Authors: Monique C. Minnema, Sanne de Haart, Tuna Mutis, Marco Koudijs, Marja van Blokland, Henk Lokhorst, Roel de Weger, Stefan Willems
Journal: Blood (2015)
Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy
Authors: Stefania Oliva, Manuela Gambella, Alessandra Larocca, Stefano Spada, Eleonora Marzanati, Barbara Mantoan, Sara Grammatico, Concetta Conticello, Barbara Gamberi, Massimo Offidani, Anna Marina Liberati, Chiara Pautasso, Paola Omedé, Antonio Palumbo, Mario Boccadoro
Journal: Blood (2016)
Anticipating High-Risk Chromosome Clonal Evolution in Chronic Lymphocytic Leukemia: A Next Generation Sequencing and Longitudinal FISH Combined Study
Authors: Ana Maria Hurtado, Chahinez Hamedi, Bartlomiej P Przychodzen, Ana I. Anton, Maria Dolores Garcia-Malo, Gloria Soler, Felipe De Arriba, Francisco Ortuño, Raul Teruel Montoya, Jaroslaw P. Maciejewski, Vicente Vicente, Andres Jerez
Journal: Blood (2014)
Association Between Baseline Corticothalamic-Mediated Inhibitory Control and Smoking Relapse Vulnerability
Authors: Brett Froeliger, Patrick A. McConnell, Spencer Bell, Maggie Sweitzer, Rachel V. Kozink, Christie Eichberg, Matt Hallyburton, Nicole Kaiser, Kevin M. Gray, F. Joseph McClernon
Journal: JAMA Psychiatry (2017)

<h3>Importance</h3> Tobacco use disorder is associated with dysregulated neurocognitive function in the right inferior frontal gyrus (IFG)—one node in a corticothalamic inhibitory control (IC) network. <h3>Objective</h3> To examine associations between IC neural circuitry structure and function and lapse/relapse vulnerability in 2 independent studies of adult smokers. <h3>Design, Setting, and Participants</h3> In study 1, treatment-seeking smokers (n = 81) completed an IC task during functional magnetic resonance imaging (fMRI) before making a quit attempt and then were followed up for 10 weeks after their quit date. In study 2, a separate group of smokers (n = 26) performed the same IC task during fMRI, followed by completing a laboratory-based smoking relapse analog task. Study 1 was performed at Duke University Medical Center between 2008 and 2012; study 2 was conducted at the Medical University of South Carolina between 2013 and 2016. <h3>Main Outcomes and Measures</h3> Associations between corticothalamic-mediated IC, gray-matter volume, and smoking lapse/relapse. <h3>Results</h3> Of the 81 study participants in study 1 (cessation study), 45 were women (56%), with mean (SD) age, 38.4 (10.2) years. In study 1, smoking relapse was associated with less gray-matter volume (<i>F</i><sub>1,74</sub> = 28.32; familywise error<i>P</i>threshold = 0.03), greater IC task-related blood oxygenation level–dependent (BOLD) response in the right IFG (<i>F</i><sub>1,78</sub> = 14.87) and thalamus (<i>F</i><sub>1,78</sub> = 14.97) (<i>P</i>&lt; .05), and weaker corticothalamic task-based functional connectivity (tbFC) (<i>F</i><sub>1,77</sub> = 5.87;<i>P</i> = .02). Of the 26 participants in study 2 (laboratory study), 15 were women (58%), with mean (SD) age, 34.9 (10.3). Similar to study 1, in study 2, greater IC-BOLD response in the right IFG (<i>t</i><sub>23</sub> = −2.49; β = −0.47;<i>P</i> = .02), and weaker corticothalamic tbFC (<i>t</i><sub>22</sub> = 5.62; β = 0.79;<i>P</i> &lt; .001) were associated with smoking sooner during the smoking relapse-analog task. In both studies, corticothalamic tbFC mediated the association between IC performance and smoking outcomes. <h3>Conclusions and Relevance</h3> In these 2 studies, baseline differences in corticothalamic circuitry function were associated with mediated IC and smoking relapse vulnerability. These findings warrant further examination of interventions for augmenting corticothalamic neurotransmission and enhancing IC during the course of tobacco use disorder treatment.
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Authors: Xiaoyan Feng, Li Zhang, Chirag Acharya, Gang An, Kenneth Wen, Lugui Qiu, Nikhil C. Munshi, Yu-Tzu Tai, Kenneth C. Anderson
Journal: Clinical Cancer Research (2017)

Purpose: We study CD38 levels in immunosuppressive CD4+CD25highFoxp3+ regulatory T cells (Treg) and further define immunomodulating effects of a therapeutic CD38 mAb isatuximab/SAR650984 in multiple myeloma.Experimental Design: We evaluated percentages of CD38-expressing subsets in Tregs from normal donors and multiple myeloma patients. Peripheral blood mononuclear cells (PBMC) were then treated with isatuximab with or without lenalidomide or pomalidomide to identify their impact on the percentage and immunosuppressive activity of Tregs on CD4+CD25- T cells (Tcons). We investigated the mechanism of increased Tregs in multiple myeloma patients in ex vivo cocultures of multiple myeloma cells with PBMCs or Tcons.Results: CD38 expression is higher on Tregs than Tcons from multiple myeloma patients versus normal donors. CD38 levels and the percentages of CD38high Tregs are increased by lenalidomide and pomalidomide. Isatuximab preferentially decreases Treg and increases Tcon frequencies, which is enhanced by pomalidomide/lenalidomide. Isatuximab reduces Foxp3 and IL10 in Tregs and restores proliferation and function of Tcons. It augments multiple myeloma cell lysis by CD8+ T and natural killer cells. Coculture of multiple myeloma cells with Tcons significantly induces Tregs (iTregs), which express even higher CD38, CD25, and FoxP3 than natural Tregs. This is associated with elevated circulating CD38+ Tregs in multiple myeloma patients versus normal donors. Conversely, isatuximab decreases multiple myeloma cell- and bone marrow stromal cell-induced iTreg by inhibiting both cell-cell contact and TGFβ/IL10. Finally, CD38 levels correlate with differential inhibition by isatuximab of Tregs from multiple myeloma versus normal donors.Conclusions: Targeting CD38 by isatuximab can preferentially block immunosuppressive Tregs and thereby restore immune effector function against multiple myeloma. Clin Cancer Res; 23(15); 4290-300. ©2017 AACR.
Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning.
Authors: Brenda M. Sandmaier, M.B. Maris, D.G. Maloney, T.A. Gooley, J.A. Shizuru, D.W. Niederwieser, T.R. Chauncey, F. Sahebi, E. Agura, R.T. Maziarz, B. Bruno, M. Pulsipher, A.A. Langston, J. Wade, P.A. McSweeney, E. Epner, W. Bethge, S.J. Forman, K.G. Blume, R. Storb
Journal: Blood (2005)
Abstract P1-04-02: Improving immunotherapy response by epigenetic modulation
Authors: N Luo, VM Estrada, ME Sanders, JM Balko
Journal: Cancer Research (2017)

Abstract The presence of predicted neo-antigens in any given tumor is highly correlated with total somatic mutational burden of the same tumor genome. However, many potential neo-antigens are never transcribed, translated, or presented as antigens, partially because they lie in regions of the genome that are transcriptionally-repressed by cytosine methylation of promoter-CpG islands. Treatment with DNA methyltransferase inhibitors (DNMTi) can hypothetically lead to re-expression of many potential neo-antigens. Furthermore, the presence of neo-antigens have been linked to immunotherapy outcomes in patients. Our hypothesis is that tumors with reduced mutational burden can be maximized for neo-antigen presentation by activating transcription and translation of these sequences through DNMTi treatment. Our preliminary results showed that the DNMTi guadecitabine (SGI-110), a second-generation hypomethylating agent, treatment decreases methyl-cytosine in genomic DNA both in vitro and in vivo. In addition, SGI-110 treatment enhances MHC-II expression on murine mammary carcinoma MMTV-Neu cells upon IFN-γ stimulation in vitro and increases T-cell infiltration in vivo. Currently, we are performing whole-exome-sequencing and RNA-sequencing to track somatic mutations from DNA to RNA. We will further track somatic mutations from RNA→ MHC-presented peptide sequences using MHC immunoprecipitation followed by mass spectroscopy analysis. In addition, we will explore the role of guadecitabine therapeutic priming on response to αPD-L1 immunotherapy. These studies will provide a pre-clinical data to evaluate the potential for combined epigenetic and immune-therapy in a clinical trial for breast cancer. Citation Format: Luo N, Estrada VM, Sanders ME, Balko JM. Improving immunotherapy response by epigenetic modulation [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-04-02.
The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia
Authors: Gautam Borthakur, Yishai Ofran, Arnon Nagler, Jacob M. Rowe, James M. Foran, Geoffrey L. Uy, John F. DiPersio, Jessica K. Altman, Olga Frankfurt, Martin S Tallman, Amnon Peled, Yaron Pereg, Abi Vainstein, Arnon Aharon, Ahmed AlRawi, Teresa McQueen, Naveen Pemmaraju, Carlos E. Bueso-Ramos, Jorge E. Cortes, Michael Andreeff
Journal: Blood (2015)
Abstract P6-07-30: Identifying novel glycosylation markers in Her2+ breast cancer using MALDI mass spectrometry
Authors: DA Scott, P Angel, H Xu, R Drake, E Yeh
Journal: Cancer Research (2017)

Abstract Breast cancer characterized by human epidermal growth factor receptor 2 (HER2) overexpression represents approximately 25-30% of all breast cancer cases. Many patients acquire resistance to current chemotherapies, leading to a more aggressive disease state with severe clinical outcomes. Lapatinib, a first generation tyrosine kinase inhibitor of HER2 and EGFR (epidermal growth factor receptor), is commonly used to treat HER2+ breast cancer. Resistance to lapatinib is steadily increasing among HER2+ patients, highlighting the need for therapy development. Identifying markers that predict treatment response or potential drug targets could enhance treatment efficacy and patient survival. To investigate this, we have used MALDI mass spectrometry to identify N-linked glycans specific to human breast cancer cell lines with known resistance and sensitivity to lapatinib treatment, JIMT-1 (resistant) HER2+ and BT474 (sensitive) HER2+. After different lapatinib dose and time course experiments, N-linked glycans were isolated and comparatively profiled by high resolution MALDI mass spectrometry. Differences in the levels of fucosylation and sialylation of glycans from sensitive and resistant cell lines, before and after treatment, were evaluated. In addition, mouse xenograft tumor tissues derived from the same cell lines treated with and without lapatinib were processed for on-tissue imaging of N-glycans using a MALDI imaging mass spectrometry approach. Tissues from HER2+ human breast tumors were also imaged with the same MALDI imaging approach. Cumulatively, these preliminary studies have identified novel glycosylation patterns associated with lapatinib treatment sensitivity and resistance. Citation Format: Scott DA, Angel P, Xu H, Drake R, Yeh E. Identifying novel glycosylation markers in Her2+ breast cancer using MALDI mass spectrometry [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-30.
Thrombopoietin Stimulates the Formation of Endothelial Cell-Cell Contacts and Activates the Small GTPase Rap1.
Authors: Marloes R. Tijssen, Franca di Summa, Anne-Marieke van Stalborch, C. Ellen Van der Schoot, Jaap D. van Buul, Peter L. Hordijk, Carlijn Voermans
Journal: Blood (2007)
P53-DEPENDENT MI-RNA TRANSCRIPTION DETERMINES MEDULLOBLASTOMA CELL SENSITIVITY TO CHEMOTHERAPEUTIC INTERVENTION
Authors: Y N Fan, D Meley, D Spiller, M White, B L Pizer, V See
Journal: Neuro-Oncology (2010)

Fan, Y. N. Meley, D. Spiller, D. White, M. Pizer, B. L. See, V. 14th International Symposium on Pediatric Neuro-Oncology Jun 20-23, 2010 Vienna, AUSTRIA
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Authors: Xuewu Zhang, Jean-Claude D Schwartz, Xiaoling Guo, Sumeena Bhatia, Erhu Cao, Michael Lorenz, Michael Cammer, Lieping Chen, Zhong-Yin Zhang, Michael A Edidin, Stanley G Nathenson, Steven C Almo
Journal: Immunity (2004)
Abstract P4-21-03: A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer
Authors: M Takahashi, Y Nishiyama, F Hara, Y Naito, M Baba, M Sasaki, M Sato, K Watanabe, Y Uemura, T Yamaguchi, H Mukai
Journal: Cancer Research (2017)

Abstract As for the HER2-positive breast cancer, there are many cases to be effective for neoadjuvant chemotherapy in comparison with other intrinsic subtypes. However, pCR is not provided by neoadjuvant chemotherapy in all cases. [Aim] This study evaluated the effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, relative to that of standard chemotherapy in patients with HER2-positive breast cancer. [patients and methods] Patients were randomly assigned to the control arm or the Ki-67 response-guided arm (Ki-67 arm). Primary tumor biopsies were obtained before treatment, and after three once-weekly doses of paclitaxel and trastuzumab to assess the interim Ki-67 index. In the control arm, paclitaxel and trastuzumab was continued for a total of 12 doses, regardless of the interim Ki-67 index. In the Ki-67 arm, subsequent treatment was based on the interim Ki-67 index. Early Ki-67 responders continued to received paclitaxel plus trastuzumab for a total of 12 doses, while early Ki-67 non-responders were switched to epirubicin plus cyclophosphamide every 3 weeks for three cycles with once-weekly trastuzumab for a total of 12 doses. The primary endpoint was the pathological complete response (pCR) rate. [Results] When 237 patients were enrolled, an interim analysis was conducted in 200 patients. There was almost linear correlation between the Ki-67 reduction rate at interim assessment and the pCR rate. The pCR rate in Ki-67 early non-responders in the Ki-67 arm (23.6%; 95% CI, 12.4 to 34.9) was inferior to that in the control arm (44.1%; 31.4 to 56.7; p=0.025). A strong correlation was not found between the Ki-67 reduction rate and the clinical response rate (Spearman's correlation coefficient 0.22). pCR rate among Ki-67 early non-responders and responders TotalpCR nn%95%CIKi-67 early non responderControl arm59264431.4-56.7 Ki-67 response guided arm55132312.4-34.9Ki-67 early responderControl arm21104726.3-69.0 Ki-67 response guided arm2084018.5-61.5 Conclusions: The pCR rate in the Ki-67 arm was inferior to that in the control arm. A therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, was not effective. The standard chemotherapy protocol remains as the recommended strategy for patients with HER2-positive breast cancer. Citation Format: Takahashi M, Nishiyama Y, Hara F, Naito Y, Baba M, Sasaki M, Sato M, Watanabe K, Uemura Y, Yamaguchi T, Mukai H. A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-03.
Autosomal dominant familial generalized pustular psoriasis caused by a <i>CARD14</i> mutation
Authors: T. Takeichi, A. Kobayashi, E. Ogawa, Y. Okuno, S. Kataoka, M. Kono, K. Sugiura, R. Okuyama, M. Akiyama
Journal: British Journal of Dermatology (2017)
What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver
Authors: Philip M Brown, Yaron Rotman
Journal: Gut (2017)

Non-alcoholic fatty liver disease (NAFLD), the excess accumulation of triglycerides in the liver, can lead to liver-associated morbidity and mortality1 and is associated with extrahepatic disorders such as diabetes, obesity and increased cardiovascular risk. NAFLD is becoming extremely prevalent, estimated to affect 30%–45% of the population in the USA.2 ,3 Given this high prevalence, the impact of NAFLD has become important in other aspects of medical care; one such aspect is liver surgery. Patients with steatosis who undergo major hepatic resection are at an increased risk for perioperative complications and mortality,4 and the regeneration of the liver postresection is slower in the obese and those with NAFLD.5 ,6 Furthermore, in liver transplantation, steatotic grafts show decreased graft survival and function.7 

Fibroblast growth factor 19 (FGF19) and its mouse ortholog Fgf15 are peptide hormones with myriad metabolic functions. Driven by luminal bile acid content and farnesoid X receptor, FGF15/19 is expressed in, and secreted from, the terminal ileum and closes the eneterohepatic feedback loop by acting on the liver to decrease hepatic bile acid synthesis. In addition, FGF15/19 regulates hepatic lipid and glucose metabolism, and affects energy expenditure and food …
History of migraine may indicate risk of ischaemic stroke
Authors: Jacqui Wise
Journal: BMJ (2017)

A history of migraine, particularly without aura, should be considered as a marker for increased risk of ischaemic stroke caused by cervical artery dissection, researchers have said in JAMA Neurology .

The multicentre Italian Project on Stroke in Young Adults study, one of the largest registries of patients with early onset ischaemic stroke, found that migraine was consistently associated with cervical artery dissection.1 …
Autologous Peripheral Blood Stem Cell Transplantation for POEMS Syndrome
Authors: Chikako Ohwada, Chiaki Nakaseko, Yusuke Takeda, Daijiro Abe, Masahiro Takeuchi, Emiko Sakaida, Shinichi Masuda, Naomi Shimizu, Ryuko Cho, Miki Nishimura, Kazuaki Kanai, Sonoko Misawa, Satoshi Kuwabara
Journal: Blood (2008)
ddClone: joint statistical inference of clonal populations from single cell and bulk tumour sequencing data
Authors: Sohrab Salehi, Adi Steif, Andrew Roth, Samuel Aparicio, Alexandre Bouchard-Côté, Sohrab P. Shah
Journal: Genome biology (2017)

Next-generation sequencing (NGS) of bulk tumour tissue can identify constituent cell populations in cancers and measure their abundance. This requires computational deconvolution of allelic counts from somatic mutations, which may be incapable of fully resolving the underlying population structure. Single cell sequencing (SCS) is a more direct method, although its replacement of NGS is impeded by technical noise and sampling limitations. We propose ddClone, which analytically integrates NGS and SCS data, leveraging their complementary attributes through joint statistical inference. We show on real and simulated datasets that ddClone produces more accurate results than can be achieved by either method alone.
A Monocentric, Prospective, Observational Study On Vaso-Occlusive Crisis (VOC) in Adult Sickle-Cell Disease (SCD).
Authors: Pablo Bartolucci, Anoosha Habibi, Mehdi Khellaf, Anne sophie Lascaux, Aline Santin, Françoise Roudot Thoraval, Stéphane Moutereau, Hélène Jouault, Yves Levy, Bertrand Renaud, Frederic Galacteros, Bertrand Godeau
Journal: Blood (2012)
A Randomised 1 Year Study Evaluating the Impact of Vitamin C Supplementation on Systemic Iron Parameters of Iron Overload in Thalassemia Major Patients on Long-Term Treatment with Deferasirox
Authors: Yesim Aydinok, Metin Delebe, Gunes Basol, Selen Bayraktaroglu, Nihal Karadas, Burcu Barutcuoglu, Eser Sozmen, Zvi Ioav Cabantchik
Journal: Blood (2016)
Efficacy and Safety of Deferasirox Estimated By Serum Ferritin and Labile Plasma Iron Levels in Patients with Aplastic Anemia, Myelodysplastic Syndrome, or Hematologic Malignancy with Transfusional Iron Overload
Authors: Il hwan Kim, Young Don Joo, Joon Ho Moon, Sung Nam Lim, Sang Kyun Sohn, Gyeong Won Lee, Ho Sup Lee, Ki Young Kwon, Sung Hyun Kim, Kyung Tae Park, Joo Seop Chung, Won Sik Lee, Sang Min Lee, Myung Soo Hyun, Hawk Kim, Hun-Mo Ryoo, Sung Hwa Bae
Journal: Blood (2014)
Spondyloarthritis: diagnosis and management: summary of NICE guidance
Authors: Katherine McAllister, Nicola Goodson, Louise Warburton, Gabriel Rogers
Journal: BMJ (2017)

#### What you need to know

Spondyloarthritis encompasses a group of inflammatory conditions with some shared features, including extra-articular manifestations that may occur at initial presentation or later. The guideline distinguishes between peripheral and axial disease (see box 1).

#### Box 1: Types of spondyloarthritis

##### Predominantly axial

##### Predominantly peripheral

Note: Predominantly axial spondyloarthritis may also have peripheral features, and vice versa

Healthcare professionals in non-specialist settings frequently fail to recognise signs and symptoms of spondyloarthritis. Axial presentations of spondyloarthritis are often misdiagnosed as mechanical low back pain, leading to delays in access to effective treatments. There is an average delay of 8.5 years between symptom onset and diagnosis, with only around 15% of cases receiving a diagnosis within three months of initial presentation.1 Contrary to common misconceptions, axial spondyloarthritis affects similar numbers of women and men, is not always apparent on plain x ray, and occurs in people who are seronegative for human leucocyte antigen …
Multiple Inhibitory Receptors Are Expressed on Central Memory and Memory Stem T Cells Infiltrating the Bone Marrow of AML Patients Relapsing after Allo-HSCT
Authors: Maddalena Noviello, Francesco Manfredi, Tommaso Perini, Giacomo Oliveira, Filippo Cortesi, Cristina Toffalori, Valentina Gambacorta, Attilio Bondanza, Raffaella Greco, Jacopo Peccatori, Giulia Casorati, Paolo Dellabona, Nicoletta Cieri, Luca Vago, Fabio Ciceri, Chiara Bonini
Journal: Blood (2016)